ABSTRACT Rats were adrenalectomized and injected for 7 days with dexamethasone (DEX) or deoxycorticosterone. Kallikrein and prekallikrein were assayed in urine and in a basolateral membrane-enriched fraction. The activities of renin and phospholipase A2 were also determined in the fraction. Adrenalectomy significantly decreased active kallikrein in urine. Administration of deoxycorticosterone raised the level of active kallikrein in urine without affecting the concentration of prekallikrein. Rats treated with DEX only had high Na' and low active kallikrein excretion. The total kallikrein level (active kallikrein together with prekallikrein), however, returned to normal because DEX elevated the prekallikrein level. DEX also increased the prekallikrein concentration in the membrane-enriched fraction. Renin activity in the membrane-enriched fraction was enhanced by adrenalectomy but suppressed by either corticosteroid. The changes in the concentration of plasma renin were qualitatively similar but quantitatively different. The activity of phospholipase A2 in the membrane-enriched fraction was enhanced only by deoxycorticosterone. Thus, both gluco-and mineralocorticoids increased kallikrein excretion in the adrenalectomized animals, but DEX was apparently effective at a lower dose than deoxycorticosterone. DEX increases the prekallikrein concentration in urine and on the basal membrane of distal tubular cells and, in addition, may prevent its conversion by releasing an inhibitor of a prekallikrein activator.
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Changes in urinary kallikrein excretion have been studied extensively in experimental animals, mainly because hypertensive patients are reported to excrete less of this hypotensive enzyme (1, 2) . In man and in animals, the excretion of urinary kallikrein increases during low sodium diet or after a mineralocorticoid has been administered for several days (1, (3) (4) (5) (6) . This effect is presumably due to the stimulation of renal kallikrein synthesis (7) . Kallikrein has been isolated in membranebound form from fractions of homogenized kidney (8) (9) (10) . It was suggested that the membrane fraction containing kallikrein originates from the distal nephron (11) , in accord with the observation that kallikrein in stop-flow experiments enters the nephron from distal tubules (12, 13) .
Two kallikreins of different physical properties have been identified in the kidney; one in a plasma membrane-enriched fraction (8) (9) (10) and the other in a basolateral membrane (BLM)-enriched fraction (14, 15) . Kallikrein derived from apical membrane can be the source of urinary kallikrein excreted at the luminal side of the nephron, while kallikrein and prekallikrein of the BLM fraction can be released into the renal venous blood and lymph (2) from the distal tubular cells (14, 15) . This latter (BLM) kallikrein has a higher molecular weight and a lower electrophoretic mobility than rat urinary kallikrein (15) .
The aim of the present studies was to determine the con- g) were anesthetized with sodium pentobarbital (50 mg/kg intraperitoneally) and the adrenals were removed. After adrenalectomy, the rats, fed with a commercial standard rat chow, were housed in individual metabolic cages.
Steroid Administration. After the animals had adapted to the metabolic cages, they were divided into four experimental groups, with 10-15 in each group. Steroids were administered starting the 8th to 10th day (1st experimental day) after adrenalectomy. Intramuscular injections were made once a day at 09:00. The groups were as follows: 1 (control; n = 14), received the vehicle (sesame oil) only; 2A and 2B (n = 13 and n = 11), received DEX at 250 and 25 ,ug; 3A and 3B (n = 15 and n = 10), received DOC at 2,500 and 250 jig; 4 (normal; n = 11), were used as the second set of controls. In addition, five adrenalectomized animals received a combination of 25 ,ug of DEX and 250 pg of DOC.
All rats were offered 0.9% saline solution as drinking fluid during the study; thus, the sodium intake of both normal and adrenalectomized animals was high. The food was removed from the cages the evening before urine collection. Urine was collected individually for 24 hr from 09:00. Blood samples were collected from the tail vein in 0.01 ml of 3.8% Na2EDTA. Rats
The publication costs ofthis article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
were decapitated in the morning on the 8th experimental day.
Tissue Fractionation. Rat BLM-enriched fractions were prepared from total kidney cortex homogenates pooled from [2] [3] [4] animals by using differential centrifugation in sucrose as previously. The BLM-enriched fraction was obtained after 18 separate washings of the sedimented proteins (14, 15 Correlations with Urinary Volume and Sodium. To determine whether active kallikrein and prekalhikrein excretion correlated with urinary volume or urinary sodium excretion, the relationship between them was determined. Active kallikrein excretion in normal intact rats correlated positively with urine volume and urinary sodium. Urinary prekalihkrein excretion in normal rats did not correlate statistically significantly with these parameters. In adrenalectomized control rats, there was a significant correlation between urinary prekallikrein and urinary volume (r = 0.83, P < 0.001) and between active kallikrein and sodium excretion (r = 0.60, P < 0.05).
In DEX-treated rats (group 2A), a significant correlation was obtained between prekallikrein and urinary sodium excretion (r = 0.73, P < 0.005). In contrast to these results, prekallikrein excretion in DOC-treated rats (group 3A) correlated highly significantly with urinary volume (r = 0.89, P < 0.001) but not with sodium excretion.
Because of the similarity in activation of tissue and urinary prekallikrein, the correlation between urinary and BLM prekallikrein in groups 1, 2A, and 3A was analyzed. In calculating been found that the lower molecular weight tissue or glandular kallikrein is also present as an inactive proenzyme in tissues such as kidney (8) and in urine (22) . To conform to the terminology used in the past literature, we refer here to the proenzyme, which is activated by trypsin, as prekallikrein.
We investigated the effects of a glucocorticoid (DEX; groups 2A and 2B) and a mineralocorticoid (DOC; groups 3A and 3B) on urinary and kidney kallikrein in adrenalectomized rats. The activity of renin was also measured.
Efforts have previously been made to find a link between kallikrein excretion, sodium metabolism, and development of high blood pressure (1, 2) . A pronounced enhancement of kallikrein excretion in aldosteronism has indeed been observed (1, 2) but aldosterone did not increase kallikrein in the perfusate of kidneys (23) . Because part of the renal kallikrein is a plasma membrane-bound enzyme, the finding that chronic administration of high doses of a mineralo-or a glucocorticoid increased the area of basolateral cell membrane of the renal cortical collecting tubules of the rabbit was of particular interest (24) . It was also reported that the area of the luminal membrane, the cell number, and the cell volume were not changed significantly by these hormones.
Adrenalectomy leads to decreased urinary kallikrein excretion in rats (3). In our experiments adrenalectomy also decreased the excretion of active urinary kallikrein. When correlation coefficients were calculated, based on determinations done in individual urine samples, it was found that the level of urinary kallikrein correlated well with the excretion of sodium while prekallikrein correlated statistically significantly with the urinary volume in adrenalectomized rats.
The origin of renin in the BLM-enriched fraction is not clear. However, it is present there, although mostly in inactive membrane-bound form, even after an isolation procedure involving 18 different washing steps (15) . Adrenalectomy increased renin activity 2-fold in the BLM fraction but more than 7-fold in plasma. A possible cause for the latter effect may be the removal of the source of aldosterone by adrenalectomy.
Effects of DOC. Urinary excretion of sodium in group 3A decreased initially on the 3rd-day (data not shown) but, by the 7th experimental day, the excretion of sodium had returned to the control level (group 1) in this group. On the 7th day, this elevation in sodium excretion due to the phenomenon of escape from mineralocorticoids coincided with an increase in kallikrein excretion. At the same time, renin activity decreased in the BLMenriched fraction. DOC administration did not affect prekallikrein either in urine or in BLM fractions of group 3A. A statistically significant correlation was found between urine volume and prekallikrein excretion in group 3A.
The increased kallikrein activity may lead to increased production of kinins. Kinins can enhance prostaglandin synthesis (25, 26) and, through this mechanism, they may affect renal hemodynamics and urinary electrolyte excretion. It has been reported that mineralocorticoids enhance urinary excretion of E-type prostaglandins in rats as a consequence of activation of the renal kallikrein-kinin system by corticosteroids (6) . We found that DOC increased phospholipase A2 activity 61% in the BLM fraction (group 3A) but DEX had no effect. This implies a hormonal control only by DOC, similar to the effect of aldosterone on the enyzme in toad bladder (27) . Since phospholipase A2 (4, 9, 28) enhances (or activates) membrane-bound kallikrein, possibly via the release of lysolecithin (9, 10, 28) , this could be a mechanism whereby mineralocorticoids enhance active kallikrein excretion.
The elevated renin concentration in plasma and in the BLM fraction brought about by removing the adrenals was lowered to less than normal by DOC.
Effects of DEX. The effects of glucocorticoid administration were more complicated. In addition to influences on renal gluconeogenesis, the physiological actions of glucocorticoids on renal handling of salt and water include modulation of the glomerular filtration rate and possibly control of the synthesis of Na+/K+-ATPase in various target segments (29, 30) removed after chronic administration. Regarding kallikrein in the perfused rat kidney, DEX increased kallikrein release in the venous effluent (23) but decreased active kallikrein excretion in intact rats (31, 32) .
We found that adrenalectomized animals indeed do excrete less active kallikrein after DEX injection but, because of the appearance of prekallikrein, which is normally low in rat urine, total kallikrein excretion was higher than in control groups (Fig.  1) . Significantly more prekallikrein was found in the BLM fraction of adrenalectomized rats that had been treated with DEX (Fig. 2) . Thus, while DOC certainly increases urinary active kallikrein (Fig. 1 ), prekallikrein appears to be under the influence of DEX.
Prekallikrein was previously found in kidney membrane fractions of rat (10, 28) and in effluents of the perfused kidney (33) but, as mentioned above, its level is very low in urine of normal or adrenalectomized rats. Kallikrein and prekallikrein in urine or DEX-treated animals had a molecular weight of about 40,000 and the same electrophoretic mobility as normal rat urinary kallikrein (15) .
It appears that glucocorticoids can enhance the synthesis of prekallikrein, but they inhibit its conversion to active kallikrein. Prekallikrein can be converted to kallikrein by serine proteases such as trypsin or plasmin (14, 15) . Administration of a glucocorticoid can lead to inhibition of an intracellular plasminogen activator (34), a serine protease that converts plasminogen to plasmin. DEX may induce the synthesis of such an inhibitor of serine proteases and thereby block the activation of prekallikrein and consequently elevate its level.
In addition, DEX may affect prekallikrein excretion indirectly by its effect on sodium and water excretion (Table 1) .
Changes in renin activity in the BLM fraction brought about by steroid treatment of adrenalectomized animals were grossly reflected by changes in plasma renin concentration. The elevated renin activity in plasma (35) or BLM fractions of rats was suppressed by DEX, but in this case administration of DEX was less effective than that of DOC.
In conclusion, it appears that active kallikrein excretion from the luminal side of the distal tubules is controlled primarily by DOC, while DEX controls prekallikrein concentration both in urine and in the basal membrane on the blood side of the nephron. The action of DEX on prekallikrein may include, in addition to stimulation of the synthesis of the proenzyme, induction or release of an inhibitor of a protease-type prekallikrein activator.
Although in these investigations steroids were used mainly in pharmacological doses, a more detailed kinetic analysis of a replacement therapy should be the subject of future studies.
